AU2003291689A8 - Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization - Google Patents

Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization

Info

Publication number
AU2003291689A8
AU2003291689A8 AU2003291689A AU2003291689A AU2003291689A8 AU 2003291689 A8 AU2003291689 A8 AU 2003291689A8 AU 2003291689 A AU2003291689 A AU 2003291689A AU 2003291689 A AU2003291689 A AU 2003291689A AU 2003291689 A8 AU2003291689 A8 AU 2003291689A8
Authority
AU
Australia
Prior art keywords
isomerization
prone
antibodies
pharmaceutical formulation
liquid pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003291689A
Other versions
AU2003291689A1 (en
Inventor
Supriya Gupta
Aleni Flores-Nate
Elizabet A Kaisheva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of AU2003291689A1 publication Critical patent/AU2003291689A1/en
Publication of AU2003291689A8 publication Critical patent/AU2003291689A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2003291689A 2002-10-31 2003-10-31 Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization Abandoned AU2003291689A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42298002P 2002-10-31 2002-10-31
US60/422,980 2002-10-31
PCT/US2003/034950 WO2004039337A2 (en) 2002-10-31 2003-10-31 Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization

Publications (2)

Publication Number Publication Date
AU2003291689A1 AU2003291689A1 (en) 2004-05-25
AU2003291689A8 true AU2003291689A8 (en) 2004-05-25

Family

ID=32230402

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003291689A Abandoned AU2003291689A1 (en) 2002-10-31 2003-10-31 Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization

Country Status (2)

Country Link
AU (1) AU2003291689A1 (en)
WO (1) WO2004039337A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1810832B (en) 1998-10-23 2012-12-12 麒麟-安姆根有限公司 Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
JP5053264B2 (en) 2005-05-19 2012-10-17 アムジェン インコーポレイテッド Compositions and methods for increasing antibody stability
JP2009502972A (en) * 2005-07-29 2009-01-29 アムジエン・インコーポレーテツド Formulation that suppresses protein aggregation
JO3324B1 (en) 2006-04-21 2019-03-13 Amgen Inc Lyophilized Therapeutic Peptibody Formulations
WO2008048430A2 (en) * 2006-10-18 2008-04-24 Amgen Inc. Identification, quantification and conversion of succinimide in proteins
MX2009003982A (en) 2006-10-20 2009-04-27 Amgen Inc Stable polypeptide formulations.
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
SG187410A1 (en) 2007-12-28 2013-02-28 Baxter Int Recombinant vwf formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
BRPI0919693A2 (en) 2008-10-21 2020-08-11 Baxter Healthcare S.A lyophilized stable pharmaceutical formulation
BRPI0921429B1 (en) 2008-11-07 2022-07-12 Takeda Pharmaceutical Company Limited STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION, AND METHOD FOR PREPARING A STABLE LYOPHILIZED FACTOR
DK3195880T3 (en) 2010-05-14 2020-03-02 Amgen Inc Highly Concentrated Anti-Sclerostin Antibody Formulations
KR102362002B1 (en) * 2013-11-29 2022-02-10 제넨테크, 인크. Antibody selection apparatus and methods
CN115925961A (en) * 2015-05-28 2023-04-07 生物辐射实验室股份有限公司 Affinity ligands and methods relating thereto
EP3615065A1 (en) 2017-04-28 2020-03-04 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
JP7307047B2 (en) 2017-07-07 2023-07-11 武田薬品工業株式会社 Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
EP3648787A1 (en) 2017-07-07 2020-05-13 Baxalta Incorporated Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
LT3681483T (en) 2017-09-15 2022-09-12 Amgen Inc. Process for lyophilized pharmaceutical formulation of a therapeutic protein
MX2020008219A (en) 2018-02-08 2020-10-22 Amgen Inc Low ph pharmaceutical antibody formulation.
US10934340B2 (en) 2018-03-21 2021-03-02 Baxalta Incorporated Separation of VWF and VWF propeptide by chromatographic methods
AU2019314355A1 (en) 2018-07-31 2021-01-28 Amgen Inc. Pharmaceutical formulations of masked antibodies
BR112021015068A2 (en) 2019-02-01 2021-10-05 Takeda Pharmaceutical Company Limited PROPHYLATIC TREATMENT METHODS USING RECOMBINANT VWF (RVWF)
MA55033A (en) 2019-02-18 2021-12-29 Lilly Co Eli THERAPEUTIC ANTIBODY FORMULATION
CN114929260A (en) 2019-09-11 2022-08-19 武田药品工业株式会社 Methods of treatment involving complexes of von willebrand factor and complement C1Q
WO2021158777A1 (en) 2020-02-04 2021-08-12 Baxalta Incorporated Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434680B (en) * 1983-01-21 1984-08-06 Karl Arne Lundblad APPLICATION OF A SALT SOLUTION OF MONOCLONAL ANTIBODIES WITH RELATIVE HIGH SALT CONTENT IN BLOOD GROUP DETERMINATION
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation

Also Published As

Publication number Publication date
AU2003291689A1 (en) 2004-05-25
WO2004039337A2 (en) 2004-05-13
WO2004039337A3 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
AU2003291689A8 (en) Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
IL176749A0 (en) ANTIBODIES TO MAdCAM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
ZA200506917B (en) Liquid pharmaceutical formulations of palonosetron
IL179250A0 (en) Stable crystal of 4-oxoquinoline compound and pharmaceutical compositions containing the same
IL163667A0 (en) Novel sustained release pharmaceutical compounds to preventabuse of controlled substances
NO20161389A1 (en) Antibodies that bind to human IGF-IR, hybridoma cell lines and nucleic acids, pharmaceutical composition comprising the same, use of the same for the preparation of pharmaceutical composition, process for the preparation of pharmaceutical composition, and uses thereof
NO20055774D0 (en) Liquid stabilized protein formulations in coated pharmaceutical containers
EP1487488A4 (en) Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
IL166809A0 (en) Pharmaceutical nati-tnf-alpha antibody formulation
IL158802A0 (en) Stable liquid formulations of antibodies
EP1660043A4 (en) Immediate-release formulation of acid-labile pharmaceutical compositions
ZA200409862B (en) Benzofused heteroaryl derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
PL375571A1 (en) Squeeze-bottle of liquid medicine
IL173930A0 (en) Pharmaceutical compositions containing forms of r-baclofen
EP1758617A4 (en) Stable liquid and lyophilized formulation of proteins
IL187957A0 (en) Liquid pharmaceutical formulations of docetaxel
IS6986A (en) Liquid pharmaceutical composition
EP1575585A4 (en) Pharmaceutical liquid composition containing pyridone derivative
ITMI20020189A0 (en) COMPOSITION FOR PHARMACEUTICAL OR DIETARY USE TO CONTRACT HAIR LOSS
EP1539156B8 (en) Liquid dosage forms of acid labile drugs
IL164464A0 (en) Antagonists to mcp proteins, their preparation, pharmaceutical composition containing them, and their use
NO20021898L (en) Pharmaceutical composition containing ciclesonide for application to mucosa
GB0328497D0 (en) Compounds which bind to the active site of protein kinase enzymes
ITMI20011989A0 (en) KIT FOR MIXING SUBSTANCES FOR THE CREATION OF COSMETIC PRODUCTS
IL173631A0 (en) Crystal forms of 1-methyl carbapenem, processes for the preparation thereof and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase